Skip to content

Pre-treatment With Methylene Blue Prevent Peri-operative Reduced Systemic Vascular Resistance

The Preventive Effects of Pre-treatment With Methylene Blue for Vascular Paralysis of the Patients With Obstructive Jaundice During Operation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03406676
Enrollment
70
Registered
2018-01-23
Start date
2017-08-01
Completion date
2018-10-30
Last updated
2018-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obstructive Jaundice

Keywords

Methylene blue; Peripheral vascular resistance

Brief summary

To explore the effects of pre-treatment with methylene blue on reduced perioperative vascular resistance in patients with obstructive jaundice.

Detailed description

Hemodynamic characteristics of patients with obstructive jaundice are high cardiac output, low peripheral vascular resistance. The molecular basis for this feature is the increased production of NO. Methylene blue can increase peripheral resistance, the mechanism is: methylene blue is an oxidoreductase inhibitor, can inhibit the increased production of NO in the vascular endothelium, thereby increasing peripheral vascular resistance.

Interventions

DRUGMethylene Blue

2mg / Kg of methylene blue in volume of 50ml is administrated I.V before anesthesia induction.

Sponsors

Southwest Hospital, China
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. Aged between 18-60 years; 2. American Society of Anesthesiologists(ASA) grade I\ III; 3. TBIL\>ULN and TBA\>ULN; The patients with obstructive jaundice.

Exclusion criteria

1. Organs dysfunction(heart,lungs and etc); 2. Mental disorders; 3. in other clinical trial.

Design outcomes

Primary

MeasureTime frameDescription
Peripheral vascular resistancethrough operation completion, an average of 6 hoursthe dose of vasoconstrictors used to Maintain Peripheral vascular resistance in the normal range (800 \ 1200dyns / cm5)

Countries

China

Contacts

Primary ContactNing Jiaolin, Doctor
Njiaolin1976@126.com0086-15808014085

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026